US EditionPublished • loading... • Updated
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement - Kalaris Therapeutics (NASDAQ:KLRS)
Summary by Benzinga
3 Articles
3 Articles
The Manila TimesReposted by 
stocktitan.net
stocktitan.netKalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) ('Kalaris”), a clinical-stage biopharmaceutical company dedicated to the...
·Manila, Philippines
Read Full Article
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement - Kalaris Therapeutics (NASDAQ:KLRS)
BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proc…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources3
Leaning Left0Leaning Right1Center1Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
